MOUNT ROYAL, N.J., June 6, 2018 /PRNewswire/ -- At the American Headache Society's (AHS) 60th Annual ScientificMeeting, leading researchers specializing in migraine, cluster headache and post-traumatic headache, will present groundbreaking data on innovative pharmacological and non-pharmacological therapies and the impact of these treatments on specific patient
Peter Goadsby, MD, PhD, FAHS, AHS Scientific Program Committee Chair, will highlight some of the data being showcased during a webcast on Thursday, June 28, 2018 at 9:00 am PDT/12:00 pm EDT. More details and registration information can be found here: https://join.onstreammedia.com/register/13415714/c74uk2a.
"The studies presented at the 60th AHS Annual Scientific Meeting deepen our understanding of headache and highlight research advances and continued progress towards more effective, better tolerated and safer treatment options," said Peter Goadsby, MD, PhD, FAHS, AHS Scientific Program Committee Chair, Professor of Neurology, King's College London, neurologist and headache specialist at University of California, San Francisco, and director, NIHR-Wellcome Trust King's Clinical Research Facility, King's College Hospital, London. "This is an unrivaled era for headache disorders, providing patients with much needed hope and concrete advances."
The AHS Annual Scientific Meeting coincides with National Migraine and Headache Awareness Month, which brings attention to the fact that migraine affects more than 36 million men, women and children in the United States and is the leading cause of disability worldwide due to a neurological disease. For more than 90% of those living with migraine, it interferes with education, career and social activities. The data to be highlighted at the AHS Annual Scientific Meeting brings new understanding of the epidemiology, as well as prevention and treatment of migraine.
The AHS has a longstanding history of sponsoring innovative science, healthcare provider education and extensive involvement of its members in leading the most pivotal clinical trials. AHS is committed to improving the lives of those with migraine and works closely in conjunction with the American Migraine Foundation, a non-profit organization founded by AHS in 2010 that is dedicated to supporting patients through education, advocacy and the advancement of migraine research.
Following is a select list of scheduled scientific presentations to come at the annual meeting (note: all times are PDT and presenters are subject to change):
Friday, June 29, 2018
Saturday, June 30, 2018
Following is a select list of abstracts that will be presented as posters:
Friday, June 29, 2018, 1:15 pm – 2:15 pm
Saturday, June 30, 2018, 1:00 pm – 2:15 pm
Online Annual Meeting Press RoomVisit https://americanheadachesociety.org/events/60th-annual-scientific-meeting/ for press guidelines and releases, as well as information on press room, press passes, embargo policies and photo/video policy.
About Peter Goadsby, MD, PhD, FAHSDr. Peter Goadsby is the AHS Scientific Program Committee Chair; Professor of Neurology, King's College London, neurologist and headache specialist at University of California, San Francisco and director, NIHR-Wellcome Trust King's Clinical Research Facility, King's College Hospital, London. His major research interests are in the basic mechanisms of primary headache disorders, such as migraine and cluster headache, in both experimental and clinical settings, and translating these insights into their better management.
About MigraineMigraine is a disabling neurological disease that affects more than 36 million men, women and children in the United States. The disease impacts one in four households, one in five women, one in 16 men and one in 11 children in the United States. The World Health Organization places migraine as one of the 10 most disabling medical illnesses on the planet. Individuals who experience migraine have symptoms that include nausea, sensitivity to light and/or odors, skin sensitivity, fatigue, mood change, dizziness, difficulty concentrating, neck pain and changes in vision, including seeing spots, stars, lines, flashing lights and zigzag lines. The risk of other serious diseases is significantly higher in those with migraine, including stroke, epilepsy, depression, anxiety and chronic pain. Despite this, only one of every three people talk with a doctor about their migraine attacks and of those, only half get the right diagnosis. There is also a shortage of specialists focusing on migraine, with only about one specialist for every 80,000 individuals living with migraine in the United States, which worsens the problem.
About the American Headache SocietyThe American Headache Society (AHS) is a professional society of healthcare providers dedicated to the study and treatment of headache and face pain. The Society's objectives are to promote the exchange of information and ideas concerning the causes and treatments of headache and related painful disorders. Educating physicians, health professionals and the public and encouraging scientific research are the primary functions of this organization. AHS activities include an annual scientific meeting, a comprehensive headache symposium, regional symposia for neurologists and family practice physicians, and publication of the journal Headache. More information can be found at www.americanheadachesociety.org. In 2010 AHS founded the American Migraine Foundation (AMF) to provide access to information and resources for individuals living with migraine, as well as their loved ones. AMF is a non-profit organization dedicated to the advancement of research and awareness surrounding migraine, with a mission to mobilize a community for patient support and advocacy, as well as drive and support impactful research that translates into treatment advances for patients with migraine and other disabling diseases that cause severe head pain. Patients can learn more, find help and get connected by visiting www.americanmigrainefoundation.org.
View original content:http://www.prnewswire.com/news-releases/the-american-headache-societys-60th-annual-scientific-meeting-to-spotlight-cutting-edge-science-novel-therapeutic-options-and-the-potential-for-improvement-in-the-lives-of-individuals-with-migraine-300660273.html
SOURCE American Headache Society
Subscribe to our Free Newsletters!
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...
Encephalocele is a birth defect where a sac like protrusion of brain and covering membranes occurs ...View All